Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim catches up with CEO and MD of Dimerix, Nina Webster.

Dimerix (ASX:DXB) focuses on chronic kidney diseases, including diabetic kidney disease.

The company’s lead drug, DMX 200, is proposed as an adjunct therapy for patients receiving irbesartan, the current standard of care treatment for kidney disease.

In the US, Dimerix has ‘orphan indication” for the kidney scarring disease FSGS (focal segmental glomerulosclerosis) and is also furthering a treatment for chronic obstructive pulmonary disease.

In early June DMX-200 was selected for inclusion in the REMAP-CAP global study protocol for Acute Respiratory Distress Syndrome caused by COVID-19.

So click below to hear all about the company’s impressive 2020 performance, drug development progress and plans for the year ahead.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!

Read MoreCOVID-19Drug Development

Featured Companies

You might be interested in